Evidence map›Paper›PMID 35955753›Full record

ArticleInternational journal of molecular sciences2022

Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.

Heejeong Kim, Han-Joo Maeng, Ji Hun Kim, Jin-Ha Yoon, Yohan Oh, Seung-Mann Paek, Yunjong Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Heejeong KimDepartment of Pharmacology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.
Han-Joo MaengCollege of Pharmacy, Gachon University, Incheon 21936, Korea.
Ji Hun KimDepartment of Pharmacology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.
Jin-Ha YoonCollege of Pharmacy, Gachon University, Incheon 21936, Korea.
Yohan OhDepartment of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.ORCID 0000-0002-9249-8664
Seung-Mann PaekCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju Daero 501, Jinju 52828, Korea.
Yunjong LeeDepartment of Pharmacology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon 16419, Korea.ORCID 0000-0003-0182-2279
Samsung (South Korea) · KRGachon University · KRGyeongsang National University · KRHanyang University · KR

Funding

Ministry of Health and Welfare HN21C1258National Research Foundation of Korea NRF-2018R1D1A1B07046762
6 · The paper itself

Abstract

Pathological protein inclusion formation and propagation are the main causes of neuronal dysfunction in diverse neurodegenerative diseases; therefore, current disease-modifying therapeutic strategies have targeted this disease protein aggregation process. Recently, we reported that peucedanocoumarin III (PCiii) is a promising therapeutic compound with the ability to disaggregate α-synuclein inclusion and protect dopaminergic neurons in Parkinson's disease (PD). Here, we found that

Indexed as

Parkinson DiseaseSynucleinopathiesalpha-SynucleinAnimalsCoumarinsDisease Models, AnimalDopaminergic NeuronsMiceRatsalpha-SynucleincoumarinCoumarinsdopaminergic cell lossorganic synthesisParkinson’s diseasepeucedanocoumarin IVpharmacokineticsα-synuclein preformed fibril

Identifiers

PMID35955753
PMCPMC9369442
OpenAlexW4289711319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.